改善肿瘤乏氧环境及乏氧应激释药型抗肿瘤药纳米递送系统研究进展

Advances in the hypoxia-responsive antitumor drug nanocarriers and tumor hypoxia relieve

乏氧是多数实体肿瘤的特征之一,影响肿瘤的侵袭和转移,是抗肿瘤药产生耐药性的一个主要原因。基于高压氧或是血液代用品递送O_2至肿瘤部位或是设计能催化肿瘤内源性H_2O_2分解产生O_2的治疗方法,提高肿瘤组织中的含氧量,改善肿瘤乏氧环境,有助于肿瘤治疗。此外,基于肿瘤乏氧微环境设计乏氧应激释药型纳米递送体系,提高靶点药物浓度,提高药物疗效并降低其不良反应。本文主要从缓解肿瘤乏氧微环境以及肿瘤乏氧微环境响应型纳米靶向递药体系进行详细综述,为研究和开发新型抗肿瘤药提供方法学借鉴。

Hypoxia, a salient feature of solid tumors, is often associated with invasiveness, metastasis and resistance to anticancer drugs. The strategies including the use of oxygen-carriers based on hyperbaric oxygen and blood substitutes to transport oxygen into tumors or in situ generation of O2 from the tumor microenvironment endogenous H2O2 have been explored to relieve the tumor hypoxia and to improve therapeutic efficiency. In addition,it is potential to design hypoxia-responsive nanocarriers based on tumor hypoxia microenvironment to deliver anticancer drugs to the targeted tumor site, thereby improve drug concentrations in targeted site, significantly increase the antitumor efficiency and reduce the side-effects of drugs. This review gives an overview of the advances in relieving tumor hypoxia and hypoxia-responsive nanocarriers for tumor to provide a reference for the research and development of new antitumor drugs.